[Kinase inhibitors and their resistance].
Kinase cascades are involved in all stages of tumorigenesis through modulation of transformation and differentiation, cell-cycle progression, and motility. Advances in molecular targeted drug development allow the design and synthesis of inhibitors targeting cancer-associated signal transduction pathways. Potent selective inhibitors with low toxicity can benefit patients especially with several malignancies harboring an oncogenic driver addictive signal. This article evaluates information on solid tumor-related kinase signals and inhibitors, including receptor tyrosine kinase or serine/threonine kinase signals that lead to successful application in clinical settings. In addition, the resistant mechanisms to the inhibitors is summarized.
Yosuke
Y
Togashi
Kazuto
K
Nishio
D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis; D000077547:Crizotinib; D055808:Drug Discovery; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors; D000077156:Gefitinib; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010879:Piperazines; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011494:Protein Kinases / Q000502:physiology*; D011720:Pyrazoles; D011725:Pyridines; D011743:Pyrimidines; D011799:Quinazolines; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D000077157:Sorafenib; D013449:Sulfonamides; D000068878:Trastuzumab; D000077484:Vemurafenib
D061067:Antibodies, Monoclonal, Humanized; D001549:Benzamides; D014408:Biomarkers, Tumor; D007211:Indoles; D010671:Phenylurea Compounds; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011743:Pyrimidines; D011799:Quinazolines; D013449:Sulfonamides; D000077484:Vemurafenib; D009536:Niacinamide; D000077547:Crizotinib; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D011494:Protein Kinases; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068878:Trastuzumab; D000077156:Gefitinib